NCT02541123已完成不适用
A Prospective Evaluation of Uch-l1 and Gfap Biomarker Kinetics After Mild Brain Injury Trauma
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 194
- 试验地点
- 10
- 主要终点
- Change in correlation of Banyan UCH-L1/GFAP Detection Assay result with acute intracranial lesions on head CT scan
研究概览
简要总结
The primary objective of the clinical trial is to evaluate the effect of time on levels of Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP) biomarker levels in a population of head injured subjects over the age of 18 presenting acutely with a Glasgow Coma Scale score 13-15 as well as in a group of uninjured control subjects.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 18 years of age at screening.
- •Presented with a suspected traumatically induced head injury, as a result of insult to the head from an external force.
- •Workup includes head CT scan, as part of clinical emergency care and CT result (CT-positive or CT-negative for acute intracranial lesions) based on the local neuroradiologist's review is available to study staff.
- •CT scan and CT report used to determine eligibility must be available.
- •Glasgow Coma Scale score of 13-15 at the time of Informed Consent.
- •Weighs at least 110lbs (50kg), has not donated blood within the last 8 weeks, and is not anemic or has any other blood disorder which requires routine transfusions.
- •First study blood sample is able to be collected into a cohort that has not been closed to enrollment
- •Able to participate for up to 11 days following head injury.
- •Subject or legal representative is willing to undergo the Informed Consent process prior to enrollment into this study.
- •FOR CT NEGATIVE COHORTS ONLY: Subject must have experienced a Loss of Consciousness (LOC) < 30 minutes, any Alteration of Consciousness (AOC), or any Post-traumatic amnesia (PTA) following the suspected head injury AND be expected to be admitted to the hospital, or remain in hospital for at least 24 hours in order to complete Visit 1 blood draws
- •Head Injured Cohorts
排除标准
- •Participating in an interventional, therapeutic clinical study that may affect the results of this study (an observational study would be acceptable).
- •Time of injury cannot be determined.
- •Primary diagnosis of ischemic or hemorrhagic stroke.
- •Venipuncture not feasible
- •Neurodegenerative disease or other neurological disorder including dementia, Parkinson's disease, multiple sclerosis, seizure disorder, or brain tumors.
- •History of neurosurgery within the last 30 days.
- •Administration of blood transfusion after head injury and prior to the study blood draw.
- •Female who is pregnant or lactating.
- •Subject is otherwise determined by the Investigator to be an unsuitable candidate for participation.
- •Control Cohort Inclusion Criteria
- •At least 18 years of age at screening
- •Weighs at least 110lbs (50kg), has not donated blood within the last 8 weeks, and is not anemic or has any other blood disorder which requires routine transfusions.
- •Healthy with no chronic or acute medical, neurologic, or psychiatric conditions (to the best of their knowledge).
- •Able to participate for up to 5 hours following the first study blood draw.
- •Willing to undergo the Informed Consent process prior to enrollment into this study.
- •Subject is able to be enrolled into a control cohort that has not yet been closed to enrollment
- •Control Cohort Exclusion Criteria
- •Participating in an interventional, therapeutic clinical study that may affect results of this study (an observational study would be acceptable).
- •Subject has sustained any significant bodily injury within the past week.
- •Venipuncture not feasible (i.e., skin integrity compromised at the venipuncture sites, blood vessel calcification (i.e., IV drug users, advanced atherosclerosis) both upper limbs missing (congenital or amputee)).
- •Neurodegenerative disease or other neurological disorder including dementia, Parkinson's disease, multiple sclerosis, seizure disorder, or brain tumors.
- •Female who is pregnant or lactating
- •History of neurosurgery within the last 30 days.
- •Subject is otherwise determined by the Investigator to be an unsuitable candidate for participation
结局指标
主要结局
Change in correlation of Banyan UCH-L1/GFAP Detection Assay result with acute intracranial lesions on head CT scan
时间窗: initial, 4hr, 8hr,12hr,16hr, 20hr, 24hr, Day 7
次要结局
未报告次要终点
研究者
研究点 (10)
Loading locations...
相似试验
已完成
不适用
EVALUATION OF BIOMARKERS OF TRAUMATIC BRAIN INJURY EXTENSION STUDYTraumatic Brain InjuryNCT02439736Banyan Biomarkers, Inc119
已完成
不适用
Evaluation of Biomarkers of Traumatic Brain InjuryTraumatic Brain InjuryNCT01426919Banyan Biomarkers, Inc2,011
已完成
1 期
Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal CancerSolid TumorColorectal CancerNCT02953782Gilead Sciences78
终止
1 期
Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's LymphomaNon Hodgkin LymphomaNCT02953509Gilead Sciences178
已完成
1 期
A Study of Olaratumab (LY3012207) in Participants With Soft Tissue SarcomaSoft Tissue SarcomaNCT02783599Eli Lilly and Company51